Privia Health

PRVA

Market cap $2.92B

The mean of analysts' price targets for Privia Health (PRVA) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago.

All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year 2025 Net Cash Provided by Operating Activities of $163.4 Million , +49.5% from 2024; Year-end 2025 Cash Balance of $479.7 Million and No Debt 2026 Guidance Reflects ~20% Adjusted EBITDA Growth at Midpoint ARLINGTON, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2025.

Evaluate the expected performance of Privia Health (PRVA) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

ARLINGTON, Va., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth-quarter and twelve-month periods ended December 31, 2025 before market open on Thursday, February 26, 2026.

Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.

Privia Health Group, Inc. ( PRVA ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Robert Borchert - Senior Vice President of Investor Relations & Corporate Communications Parth Mehrotra - CEO & Director David Mountcastle - Executive VP, CFO & Principal Accounting Officer Conference Call Participants Marco Criscuolo - Nephron Research LLC Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Thomas Walsh - Barclays Bank PLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Ryan Langston - TD Cowen, Research Division Albert Rice - UBS Investment Bank, Research Division Constantine Davides - Citizens JMP Securities, LLC, Research Division Derek Gross - Piper Sandler & Co., Research Division Daniel Grosslight - Citigroup Inc., Research Division Jack Slevin - Jefferies LLC, Research Division Jenny Shen - BTIG, LLC, Research Division Ryan Daniels - William Blair & Company L.L.C., Research Division Presentation Operator Hello, and welcome to the Privia Health Third Quarter 2025 Results Conference Call.

The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.